Protocol Ledger

NCT06730373 · Phase II · RECRUITING

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Interventional Phase II clinical trial protocol NCT06730373 sponsored by Qilu Hospital of Shandong University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-17 Enrollment: 110 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06730373
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06730373
Protocol FieldVerified Registry Value
NCT IdentifierNCT06730373
Consolidated Lead SponsorQilu Hospital of Shandong University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment110 participants (ESTIMATED)
Registered Start Date2024-10-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06730373
Hospital Research SiteLocationSite Profile
The first affiliated hospital of Zhengzhou UniversityZhengzhou, ChinaOpen Hospital Dossier ->
Liaocheng People's hospitalLiaocheng, ChinaOpen Hospital Dossier ->
Linyi Cancer HospitalLinyi, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI